Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3470 Monotherapy and Combination With Pembrolizumab in Haematologic Malignancies (PRIMAVERA)
jRCT2031260260Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of AZD3470 in classical Hodgkin lymphoma (cHL), peripheral T-cell lymphoma (PTCL), systemic anaplastic large cell lymphoma (ALCL) and 1 more (3 cohorts), sponsored by AstraZeneca. Primary endpoints: Incidence and severity of adverse events, Incidence and severity of serious adverse events and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
AZD3470
03
Conditions
classical Hodgkin lymphoma (cHL)peripheral T-cell lymphoma (PTCL)systemic anaplastic large cell lymphoma (ALCL)angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on jRCT2031260260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260260.